目的:探讨乳腺癌组织FK506结合蛋白38(FK506-binding protein 38,FKBP38)的表达水平及其与病理分级和临床分期的关系。方法:采用免疫组化检测100例正常乳腺组织、300例浸润性导管癌(Invasion ductal carcinoma,IDC)和59例浸润性小叶癌组...目的:探讨乳腺癌组织FK506结合蛋白38(FK506-binding protein 38,FKBP38)的表达水平及其与病理分级和临床分期的关系。方法:采用免疫组化检测100例正常乳腺组织、300例浸润性导管癌(Invasion ductal carcinoma,IDC)和59例浸润性小叶癌组织(Invasion lobular carcinoma,ILD)中FKBP38的表达水平,分析FKBP38蛋白表达水平与乳腺癌临床病理参数之间的关系。结果:免疫组化结果表明,与正常乳腺组织相比,FKBP38在浸润性导管癌及浸润性小叶癌组织中的表达水平均显著降低,具有统计学差异(P<0.0001)。通过进一步分析可知,在浸润性导管癌中,FKBP38蛋白表达水平随病理分级及临床分期的增加而降低,具有统计学差异,而FKBP38蛋白与孕激素受体(Progesterone receptor,PR)蛋白的表达呈负相关。此外,三阴性乳腺癌(Triple-negative breast cancer,TNBC)FKBP38的表达水平显著高于非三阴性乳腺癌,同样,FKBP38在TNBC的表达水平随原发性肿瘤分期的增加而降低。结论:FKBP38蛋白水平在乳腺癌患者中表达水平显著降低,并与乳腺癌的病理分级、临床分期相关。这提示FKBP38蛋白水平可作为乳腺癌诊断和治疗的潜在靶点,但其作用机制仍需进一步研究。展开更多
目的:探讨卵巢上皮性肿瘤中FK506结合蛋白38(FK506-binding protein 38,FKBP38)蛋白的表达及潜在的临床意义。方法:采用免疫组化的方法检测20例正常输卵管组织,30例卵巢上皮性良性肿瘤,27例卵巢交界性肿瘤组织,130例卵巢上皮性癌(epithe...目的:探讨卵巢上皮性肿瘤中FK506结合蛋白38(FK506-binding protein 38,FKBP38)蛋白的表达及潜在的临床意义。方法:采用免疫组化的方法检测20例正常输卵管组织,30例卵巢上皮性良性肿瘤,27例卵巢交界性肿瘤组织,130例卵巢上皮性癌(epithelial ovarian carcinoma,EOC)组织中FKBP38蛋白的表达,并分析其表达水平与临床病理参数的关系。结果:FKBP38蛋白在卵巢上皮性癌中的表达明显低于正常输卵管组织、卵巢上皮性良性和交界性肿瘤组织,差异有统计学意义(P<0.05)。FKBP38蛋白表达在根据国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)标准定义的不同分期的卵巢上皮性癌组织中具有统计学差异(P<0.05)。FKBP38蛋白在卵巢高级别浆液性癌的表达比低级别浆液性癌中的表达显著性降低(P<0.05)。但把卵巢上皮性癌按照不同年龄及不同组织学分型分层后,FKBP38蛋白表达差异无统计学意义(P>0.05)。结论:FKBP38蛋白表达的下调可能与卵巢上皮性癌的发生和分化密切相关,提示FKBP38蛋白作为卵巢恶性肿瘤诊断和治疗的潜在性生物靶点需进一步探索和研究。展开更多
The mammalian target of rapamycin(mTOR)-sterol regulatory element-binding proteins(SREBPs)signaling promotes lipogenesis.However,mTOR inhibitors also displayed a significant side effect of hyperlipidemia.Thus,it is es...The mammalian target of rapamycin(mTOR)-sterol regulatory element-binding proteins(SREBPs)signaling promotes lipogenesis.However,mTOR inhibitors also displayed a significant side effect of hyperlipidemia.Thus,it is essential to develop mTOR-specific inhibitors to inhibit lipogenesis.Here,we screened the endogenous inhibitors of mTOR,and identified that FKBP38 as a vital regulator of lipid metabolism.FKBP38 decreased the lipid content in vitro and in vivo via suppression of the mTOR/P70 S6 K/SREBPs pathway.3,5,6,7,8,3’,4’-Heptamethoxyflavone(HMF),a citrus flavonoid,was found to target FKBP38 to suppress the mTOR/P70 S6 K/SREBPs pathway,reduce lipid level,and potently ameliorate hyperlipidemia and insulin resistance in high fat diet(HFD)-fed mice.Our findings suggest that pharmacological intervention by targeting FKBP38 to suppress mTOR/P70 S6 K/SREBPs pathway is a potential therapeutic strategy for hyperlipidemia,and HMF could be a leading compound for development of anti-hyperlipidemia drugs.展开更多
文摘目的:探讨乳腺癌组织FK506结合蛋白38(FK506-binding protein 38,FKBP38)的表达水平及其与病理分级和临床分期的关系。方法:采用免疫组化检测100例正常乳腺组织、300例浸润性导管癌(Invasion ductal carcinoma,IDC)和59例浸润性小叶癌组织(Invasion lobular carcinoma,ILD)中FKBP38的表达水平,分析FKBP38蛋白表达水平与乳腺癌临床病理参数之间的关系。结果:免疫组化结果表明,与正常乳腺组织相比,FKBP38在浸润性导管癌及浸润性小叶癌组织中的表达水平均显著降低,具有统计学差异(P<0.0001)。通过进一步分析可知,在浸润性导管癌中,FKBP38蛋白表达水平随病理分级及临床分期的增加而降低,具有统计学差异,而FKBP38蛋白与孕激素受体(Progesterone receptor,PR)蛋白的表达呈负相关。此外,三阴性乳腺癌(Triple-negative breast cancer,TNBC)FKBP38的表达水平显著高于非三阴性乳腺癌,同样,FKBP38在TNBC的表达水平随原发性肿瘤分期的增加而降低。结论:FKBP38蛋白水平在乳腺癌患者中表达水平显著降低,并与乳腺癌的病理分级、临床分期相关。这提示FKBP38蛋白水平可作为乳腺癌诊断和治疗的潜在靶点,但其作用机制仍需进一步研究。
文摘目的:探讨卵巢上皮性肿瘤中FK506结合蛋白38(FK506-binding protein 38,FKBP38)蛋白的表达及潜在的临床意义。方法:采用免疫组化的方法检测20例正常输卵管组织,30例卵巢上皮性良性肿瘤,27例卵巢交界性肿瘤组织,130例卵巢上皮性癌(epithelial ovarian carcinoma,EOC)组织中FKBP38蛋白的表达,并分析其表达水平与临床病理参数的关系。结果:FKBP38蛋白在卵巢上皮性癌中的表达明显低于正常输卵管组织、卵巢上皮性良性和交界性肿瘤组织,差异有统计学意义(P<0.05)。FKBP38蛋白表达在根据国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)标准定义的不同分期的卵巢上皮性癌组织中具有统计学差异(P<0.05)。FKBP38蛋白在卵巢高级别浆液性癌的表达比低级别浆液性癌中的表达显著性降低(P<0.05)。但把卵巢上皮性癌按照不同年龄及不同组织学分型分层后,FKBP38蛋白表达差异无统计学意义(P>0.05)。结论:FKBP38蛋白表达的下调可能与卵巢上皮性癌的发生和分化密切相关,提示FKBP38蛋白作为卵巢恶性肿瘤诊断和治疗的潜在性生物靶点需进一步探索和研究。
基金financial support from the National Natural Science Foundation of China(81922072 and 81973443)“Double First-Class”University project(CPU2018PZQ16 and CPU2018GF04,China)+2 种基金the Project of State Key Laboratory of Natural Medicines(SKLNMZZ202006,China)the Open Project of State Key Laboratory of Natural Medicines(SKLNMKF202010,China)a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions(China)。
文摘The mammalian target of rapamycin(mTOR)-sterol regulatory element-binding proteins(SREBPs)signaling promotes lipogenesis.However,mTOR inhibitors also displayed a significant side effect of hyperlipidemia.Thus,it is essential to develop mTOR-specific inhibitors to inhibit lipogenesis.Here,we screened the endogenous inhibitors of mTOR,and identified that FKBP38 as a vital regulator of lipid metabolism.FKBP38 decreased the lipid content in vitro and in vivo via suppression of the mTOR/P70 S6 K/SREBPs pathway.3,5,6,7,8,3’,4’-Heptamethoxyflavone(HMF),a citrus flavonoid,was found to target FKBP38 to suppress the mTOR/P70 S6 K/SREBPs pathway,reduce lipid level,and potently ameliorate hyperlipidemia and insulin resistance in high fat diet(HFD)-fed mice.Our findings suggest that pharmacological intervention by targeting FKBP38 to suppress mTOR/P70 S6 K/SREBPs pathway is a potential therapeutic strategy for hyperlipidemia,and HMF could be a leading compound for development of anti-hyperlipidemia drugs.
